Skip to main content
OpenTrials
Completed

NCT Number: NCT01807702

13C-Pyruvate Breath Test

The purpose of the test is to measure an enzyme called pyruvate. Subjects will fast for 12 hours and then undergo a breath test, have blood drawn, and cells from the inside of the mouth collected over a 12 hour period. The tests will be repeated at least a week later and subjects receive a dose of dichloroacetate (DCA)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Florida

Gainesville, Florida, 32610, United States

About this study

Subjects will be screened with a history and physical and have baseline laboratory values drawn to assure that the subject is healthy.Subjects will fast for 12 hours before the test. The next day they will receive a dose of 25mg of pyruvate dissolved in 80ml of Crystal Light. The pyruvate used in this study will be prepared with a nonradioactive form of carbon, called a stable isotope. It poses no hazard to the subject's health. About 50 mls of blood will be drawn over a 120 minute time period from an IV catheter placed in the arm. Subjects will also be asked to exhale into a plastic tube about 12 times in 120 minutes to collect 13C carbon dioxide (13CO2). Cells from inside of the mouth will be collected by subjects swishing a tablespoon of mouth wash for one minute and then spitting it into a sterile plastic tube. At least one week following the first admission subjects will return to repeat the above procedure and receive 25mg of dichloroacetate (DCA) one hour before receiving the pyruvate. Then the same samples will be collected. Subjects have the option of doing the tests 4 times receiving the DCA on the last visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- healthy volunteers

  • normal history,
  • normal physical
  • normal baseline laboratory data.

Exclusion criteria

  • Any illness
  • Chronic health condition
  • Use of street drugs
  • Taking medication
  • Abnormal labs Abnormal physical exam -

Treatment and study plan

13C-Pyruvate 13C-lactate and dichloroacetate

Drug

Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given

Other names: dichloroacetate, pyruvate, CO2 collection

Primary outcomes

  1. Effect of dichloroacetate on pyruvate dehydrogenase and 13C02 production.

    Time frame: Baseline to one year

    Dichloroacetate is an activator of pyruvate dehydrogenase (PDH). It will be administered to the patient who will then undergo the pyruvate breath test to measure the amount of 13CO2 expressed. The activity of 13CO2 as measured by a concentration curve will reflect PDH activity.

Secondary outcomes

  1. Blood Lactate levels and 13CO2 Response to DCA

    Time frame: Baseline to one year

    There will be a correlation between blood lactate levels and 13CO2 in response to DCA administration by comparing CO2 breath peaks in the concentration curve compared to serum lactate levels for same time period.

  2. Conversion of 13C pyruvate to 13C pyruvate

    Time frame: Baseline to One Year

    There will be no reduction in the conversion of 13C-pyruvate to 13C-lactate in blood in response to DCA administration.

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Registry information

Official study title

13C-Pyruvate Breath Test Pilot Study

Acronym: PBT

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Mar 8, 2013
Registry last updated
Dec 2, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.